Alan Grover
Ophthalmology · Fayetteville, ARNPI 1760672331
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $316, 3.7 times the $85 reported in 2019.
Across 63 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$288
- Tarsus Pharmaceuticals, Inc.$132
- AbbVie$130
- Bausch & Lomb, A Division Of Bausch Health US, LLC$121
- Johnson & Johnson Vision Care, Inc.$111
- Biotissue Holdings Inc.$92
- plus $341 from 12 others
What the payments were for
- Food & beverage$1,216100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 14 | $288 |
| Tarsus Pharmaceuticals, Inc. | 7 | $132 |
| AbbVie(2 entities) | 7 | $130 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $121 |
| Johnson & Johnson Vision Care, Inc. | 6 | $111 |
| Biotissue Holdings Inc. | 3 | $92 |
| Kala Pharmaceuticals, Inc. | 3 | $59 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Amgen | 2 | $39 |
| Rayner Intraocular Lenses Limited | 2 | $34 |
| Novartis | 2 | $31 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Glaukos Corporation | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Alcon | 1 | $15 |
| Sight Sciences, Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
How this compares
$1,216 in reported general payments places this provider in the 60th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 35 | $26,678 |
| LumiganBimatoprost | 12 | $7,082 |
| Loteprednol Etabonate | 17 | $1,958 |
| Brimonidine Tartrate | 43 | $1,855 |
| Fluorometholone | 13 | $952 |
| Latanoprost | 69 | $834 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $423 |
| Timolol Maleate | 42 | $292 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $130 | $33,76047 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $121 | $1,95817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Fayetteville
- Peter DautFayetteville$4K
- Sarah CoveyFayetteville$2K
- Eddie MengarelliFayetteville$2K
- Paul HenryFayetteville$2K
- Patrick RischFayetteville$2K
- Chad BettsFayetteville$1K
- Craig BrownFayetteville$797
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.